NEW YORK (AP) - Generic drugmaker Ranbaxy Laboratories Ltd. said Tuesday its U.S. subsidiary received final U.S. Food and Drug Administration approval on two generic doses of the migraine drug Imitrex.

The India-based company said it will start shipping the 25-milligram and 50-milligram doses of the drug immediately.

U.K.-based GlaxoSmithKline PLC makes the drug, which also carries the generic name sumatriptan. Ranbaxy said sales of the 25-milligram and 50-milligram doses of the drug reached $379 million over the year ended June 30, citing market researcher IMS Health Inc.

On Monday, Canonsburg, Pa.-based generic drug developer Mylan Inc. said it started shipping generic versions of the drug.

GlaxoSmithKline has a facility in Memphis.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.